In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
Matthias Evers is Evotec’s chief business officer • Source: Evotec
In a major deal for the off-patent industry, Sandoz recently announced a multi-year collaboration with Evotec subsidiary Just-Evotec Biologics that will see the firms develop and manufacture multiple biosimilars together.
The alliance – which Sandoz’s biosimilars head saidwould be “a game-changer” for the firm’s biopharma business (Also see "Slovenia...
